# 21 CFR Part 201—Labeling

21 CFR Part 201—Labeling, “Labeling”, is a CFR part of [21 CFR Chapter I, Subchapter C—DRUGS: GENERAL](https://ontology.bommaritollc.com/id/01a0f094-b59c-71c5-9205-607bcccd7551); it is made under 42 laws; in force.

IRI: <https://ontology.bommaritollc.com/id/01a0f094-b837-76de-94de-1fdabf2c1fc1>

Within: [Title 21—Food and Drugs](https://ontology.bommaritollc.com/id/01a0f094-b437-7426-9a1d-f0a9f3d3e1aa) › [21 CFR Chapter I—FOOD AND DRUG ADMINISTRATION, DEPARTMENT OF HEALTH AND HUMAN SERVICES](https://ontology.bommaritollc.com/id/01a0f094-b455-74b7-9458-ed95d7b5ea58) › [21 CFR Chapter I, Subchapter C—DRUGS: GENERAL](https://ontology.bommaritollc.com/id/01a0f094-b59c-71c5-9205-607bcccd7551)

Type: [schema:Legislation](https://schema.org/Legislation)

- `adms:identifier`: [cfr-part 21 CFR Part 201](https://ontology.bommaritollc.com/id/01a0f094-b838-7679-b30b-c2b608cf1f8b)
- **authority note** (`bcleg:authorityNote`): 21 U.S.C. 321, 331, 343, 351, 352, 353, 355, 358, 360, 360b, 360ccc, 360ccc-1, 360ee, 360gg-360ss, 371, 374, 379e; 42 U.S.C. 216, 241, 262, 264.
- `eli:based_on`:
  - [21 U.S.C. 321 Definitions; generally](https://ontology.bommaritollc.com/id/01a0f06c-cc8c-7030-ab68-1def0b197dcb)
  - [21 U.S.C. 331 Prohibited acts](https://ontology.bommaritollc.com/id/01a0f06c-cc92-7163-972f-ca345be44724)
  - [21 U.S.C. 343 Misbranded food](https://ontology.bommaritollc.com/id/01a0f06c-cca3-7182-b25e-3e24d5de5215)
  - [21 U.S.C. 351 Adulterated drugs and devices](https://ontology.bommaritollc.com/id/01a0f06c-ccc8-7536-94e4-d8e798dad75a)
  - [21 U.S.C. 352 Misbranded drugs and devices](https://ontology.bommaritollc.com/id/01a0f06c-ccca-77a6-a36b-8f6a7374070e)
  - [21 U.S.C. 353 Exemptions and consideration for certain drugs, devices, and biological products](https://ontology.bommaritollc.com/id/01a0f06c-cccb-7545-90e2-a1651be32192)
  - [21 U.S.C. 355 New drugs](https://ontology.bommaritollc.com/id/01a0f06c-ccd6-7038-b7ea-5f9e1b3b3f50)
  - [21 U.S.C. 358 Authority to designate official names](https://ontology.bommaritollc.com/id/01a0f06c-ccf9-704b-8dfc-d48c5f351545)
  - [21 U.S.C. 360 Registration of producers of drugs or devices](https://ontology.bommaritollc.com/id/01a0f06c-ccfb-75a5-8f8d-2899cf8ac727)
  - [21 U.S.C. 360b New animal drugs](https://ontology.bommaritollc.com/id/01a0f06c-cd00-76d9-bb38-b67fe8155231)
  - [21 U.S.C. 360h Notification and other remedies](https://ontology.bommaritollc.com/id/01a0f06c-cd10-74c2-91eb-0ad7ee0450e1)
  - [21 U.S.C. 360h-1 Program to improve the device recall system](https://ontology.bommaritollc.com/id/01a0f06c-cd11-76bf-bcc7-d463de58e649)
  - [21 U.S.C. 360i Records and reports on devices](https://ontology.bommaritollc.com/id/01a0f06c-cd12-7312-ba25-7c772f32c7e0)
  - [21 U.S.C. 360j General provisions respecting control of devices intended for human use](https://ontology.bommaritollc.com/id/01a0f06c-cd14-70a5-a599-4fff974986bc)
  - [21 U.S.C. 360k State and local requirements respecting devices](https://ontology.bommaritollc.com/id/01a0f06c-cd15-71c4-9fb5-662cdb21fb29)
  - [21 U.S.C. 360l Postmarket surveillance](https://ontology.bommaritollc.com/id/01a0f06c-cd17-76ed-89af-389751edcbcb)
  - [21 U.S.C. 360m Accredited persons](https://ontology.bommaritollc.com/id/01a0f06c-cd18-7362-b421-8100446be7f2)
  - [21 U.S.C. 360n Priority review to encourage treatments for tropical diseases](https://ontology.bommaritollc.com/id/01a0f06c-cd19-726a-ab96-7d5287064803)
  - [21 U.S.C. 360n-1 Priority review for qualified infectious disease products](https://ontology.bommaritollc.com/id/01a0f06c-cd1a-71cb-a82f-2a31a0f57ae0)
  - [21 U.S.C. 360n-2 Ensuring cybersecurity of devices](https://ontology.bommaritollc.com/id/01a0f06c-cd1c-7386-ac80-109afa0a4867)
  - [21 U.S.C. 360ee Grants and contracts for development of drugs for rare diseases and conditions](https://ontology.bommaritollc.com/id/01a0f06c-cd22-753d-b72f-bdb9875c6f44)
  - [21 U.S.C. 360hh Definitions](https://ontology.bommaritollc.com/id/01a0f06c-cd27-7678-8861-5cc56b55baad)
  - [21 U.S.C. 360ii Program of control](https://ontology.bommaritollc.com/id/01a0f06c-cd28-72e7-a6c8-581b4cdb0e49)
  - [21 U.S.C. 360jj Studies by Secretary](https://ontology.bommaritollc.com/id/01a0f06c-cd29-7140-8d32-898bf0c2ecd0)
  - [21 U.S.C. 360kk Performance standards for electronic products](https://ontology.bommaritollc.com/id/01a0f06c-cd2b-778b-98f6-39e1a589a99e)
  - [21 U.S.C. 360ll Notification of defects in and repair or replacement of electronic products](https://ontology.bommaritollc.com/id/01a0f06c-cd2c-7261-8058-bc577f61ece3)
  - [21 U.S.C. 360mm Imports](https://ontology.bommaritollc.com/id/01a0f06c-cd2e-7500-ab42-b9fb73a66b4e)
  - [21 U.S.C. 360nn Inspection, records, and reports](https://ontology.bommaritollc.com/id/01a0f06c-cd2f-74ab-9387-c7faab2886e8)
  - [21 U.S.C. 360oo Prohibited acts](https://ontology.bommaritollc.com/id/01a0f06c-cd31-7053-bc6c-03a7ba26c3bf)
  - [21 U.S.C. 360pp Enforcement](https://ontology.bommaritollc.com/id/01a0f06c-cd32-71d2-8be0-5012ccdd4cf5)
  - [21 U.S.C. 360qq Repealed. Pub. L. 105–362, title VI, §601(a)(2)(A), Nov. 10, 1998, 112 Stat. 3285](https://ontology.bommaritollc.com/id/01a0f06c-cd33-7044-a1dd-b7e3e8febd0f)
  - [21 U.S.C. 360rr Federal-State cooperation](https://ontology.bommaritollc.com/id/01a0f06c-cd34-7484-821a-0cf585a20700)
  - [21 U.S.C. 360ss State standards](https://ontology.bommaritollc.com/id/01a0f06c-cd35-7577-9011-bdaf956a50c7)
  - [21 U.S.C. 360ccc Conditional approval of new animal drugs for minor use and minor species and certain new animal drugs](https://ontology.bommaritollc.com/id/01a0f06c-cd53-7391-a7b5-2ff718662d9e)
  - [21 U.S.C. 360ccc-1 Index of legally marketed unapproved new animal drugs for minor species](https://ontology.bommaritollc.com/id/01a0f06c-cd54-7596-8cfd-a8ca0a70d58b)
  - [21 U.S.C. 371 Regulations and hearings](https://ontology.bommaritollc.com/id/01a0f06c-cd7f-7552-9512-d5162892046d)
  - [21 U.S.C. 374 Inspection](https://ontology.bommaritollc.com/id/01a0f06c-cd83-7175-9624-79d9d7728390)
  - [21 U.S.C. 379e Listing and certification of color additives for foods, drugs, devices, and cosmetics](https://ontology.bommaritollc.com/id/01a0f06c-cd98-7399-b68d-fe6ae17270b5)
  - [42 U.S.C. 216 Regulations](https://ontology.bommaritollc.com/id/01a0f07c-d8ec-7255-a4c6-81e69a8fe61c)
  - [42 U.S.C. 241 Research and investigations generally](https://ontology.bommaritollc.com/id/01a0f07c-d91a-755c-82c6-9622b6fcae5b)
  - [42 U.S.C. 262 Regulation of biological products](https://ontology.bommaritollc.com/id/01a0f07c-d9ca-7203-a1d8-2d79c0329140)
  - [42 U.S.C. 264 Regulations to control communicable diseases](https://ontology.bommaritollc.com/id/01a0f07c-da01-7612-a2fd-2f3800f7d8af)
- `prov:wasDerivedFrom`:
  - [evidence from https://www.govinfo.gov/app/details/CFR-2025-title21-vol4](https://ontology.bommaritollc.com/id/01a0f094-b837-76de-94de-1fd9936569f5)
  - [evidence from https://www.govinfo.gov/app/details/](https://ontology.bommaritollc.com/id/01a0f094-da1b-7773-a574-88e511fb924c)
  - [evidence from https://www.govinfo.gov/app/details/](https://ontology.bommaritollc.com/id/01a0f0cf-7d30-7026-8463-3907db15f69c)
  - [evidence from https://www.govinfo.gov/link/cfr/21/201?year=mostrecent&link-type=details](https://ontology.bommaritollc.com/id/01a10f16-3eba-7430-bad3-f73843e18486)
- `schema:isPartOf`: [21 CFR Chapter I, Subchapter C—DRUGS: GENERAL](https://ontology.bommaritollc.com/id/01a0f094-b59c-71c5-9205-607bcccd7551)
- `schema:legislationIdentifier`: 21 CFR Part 201
- `schema:legislationJurisdiction`: [United States](https://ontology.bommaritollc.com/id/01a0ed8e-f797-7004-b7f5-bec2695977c0)
- `schema:legislationLegalForce`: [schema:InForce](https://schema.org/InForce)
- `schema:legislationType`: [CFR part](https://ontology.bommaritollc.com/vocab/leg/cfrPart)
- `schema:name`: Labeling
- `schema:url`: [https://www.govinfo.gov/link/cfr/21/201?year=mostrecent&link-type=details](https://www.govinfo.gov/link/cfr/21/201?year=mostrecent&link-type=details)
- `skos:prefLabel`: 21 CFR Part 201—Labeling
- **source note** (`bcleg:sourceNote`): 40 FR 13998, Mar. 27, 1975, unless otherwise noted.

## Elsewhere

- [Official page](https://www.govinfo.gov/link/cfr/21/201?year=mostrecent&link-type=details) (www.govinfo.gov)
- [Source](https://www.govinfo.gov/app/details/CFR-2025-title21-vol4) (www.govinfo.gov)
- [Source](https://www.govinfo.gov/app/details/) (www.govinfo.gov)

## Pointing here

- Cited by (8; `eli:cites`):
  - [21 CFR 207.1 What definitions and interpretations of terms apply to this part?](https://ontology.bommaritollc.com/id/01a0f094-c378-72ea-8da6-b37888541a78)
  - [21 CFR 251.13 Labeling of eligible prescription drugs.](https://ontology.bommaritollc.com/id/01a0f094-c45e-7356-b458-c9e7394d2025)
  - [21 U.S.C. 355h Regulation of certain nonprescription drugs that are marketed without an approved drug application](https://ontology.bommaritollc.com/id/01a0f06c-cce3-7057-a5e9-bb0e6598808a)
  - [FR Doc. 2023-11354: Medication Guides: Patient Medication Information](https://ontology.bommaritollc.com/id/01a110b2-7414-70fb-8350-7fb0927d1ff3)
  - [FR Doc. 2024-04840: Labeling Requirements for Approved or Conditionally Approved New Animal Drugs](https://ontology.bommaritollc.com/id/01a110b3-3a77-7639-bb47-5b110a378093)
  - [FR Doc. 2024-11229: Labeling Requirements for Approved or Conditionally Approved New Animal Drugs; Extension of Comment Period](https://ontology.bommaritollc.com/id/01a110b3-64b2-75f2-ae08-1d2d277db654)
  - [FR Doc. 2026-08826: Modification of Certain Terminology in Title 21](https://ontology.bommaritollc.com/id/01a110b5-323e-7153-ad6c-31838574bc35)
  - [FR Doc. 2026-15671: Modification of Certain Terminology in Title 21; Reopening of the Comment Period](https://ontology.bommaritollc.com/id/01a110b5-74c0-722c-9a1e-da752f27c32c)
- Parts (7; `schema:isPartOf`):
  - [21 CFR Part 201, Subpart A—General Labeling Provisions](https://ontology.bommaritollc.com/id/01a0f094-b5a0-730a-8f1e-9edc8b8a21e6)
  - [21 CFR Part 201, Subpart B—Labeling Requirements for Prescription Drugs and/or Insulin](https://ontology.bommaritollc.com/id/01a0f094-b5a1-77fd-9e9f-0960df2f7eb1)
  - [21 CFR Part 201, Subpart C—Labeling Requirements for Over-the-Counter Drugs](https://ontology.bommaritollc.com/id/01a0f094-b5a1-77fd-9e9f-096d0ad46262)
  - [21 CFR Part 201, Subpart D—Exemptions From Adequate Directions for Use](https://ontology.bommaritollc.com/id/01a0f094-b5a2-733b-b9d3-6c4c7a630886)
  - [21 CFR Part 201, Subpart E—Other Exemptions](https://ontology.bommaritollc.com/id/01a0f094-b5a2-733b-b9d3-6c595d1dfdef)
  - [21 CFR Part 201, Subpart F—Labeling Claims for Drugs in Drug Efficacy Study](https://ontology.bommaritollc.com/id/01a0f094-b5a3-701f-a765-9baefb8ea0b9)
  - [21 CFR Part 201, Subpart G—Specific Labeling Requirements for Specific Drug Products](https://ontology.bommaritollc.com/id/01a0f094-b5aa-7634-9007-dbb34d9cb1b2)
- Its changes, from (5; `eli:changes`):
  - [FR Doc. 2024-13190: Current Good Manufacturing Practice, Certification, Postmarketing Safety Reporting, and Labeling Requirements for Certain Medical Gases](https://ontology.bommaritollc.com/id/01a110b3-7411-71f8-beba-a48901157d9c)
  - [FR Doc. 2024-30261: Nonprescription Drug Product With an Additional Condition for Nonprescription Use](https://ontology.bommaritollc.com/id/01a110b3-e4cd-765a-8ff9-8ee3a79ad81a)
  - [FR Doc. 2025-01840: Nonprescription Drug Product With an Additional Condition for Nonprescription Use](https://ontology.bommaritollc.com/id/01a110b3-f5da-720e-be5b-ddec89c4e54f)
  - [FR Doc. 2025-04978: Nonprescription Drug Product With an Additional Condition for Nonprescription Use](https://ontology.bommaritollc.com/id/01a110b4-09da-7626-a221-4c1f9c59cab3)
  - [FR Doc. 2026-04368: Revising the National Drug Code Format and Drug Label Barcode Requirements](https://ontology.bommaritollc.com/id/01a110b5-1035-74e8-92e3-20bbddac1c32)

---
Also as: [Turtle](https://ontology.bommaritollc.com/id/01a0f094-b837-76de-94de-1fdabf2c1fc1.ttl), [JSON-LD](https://ontology.bommaritollc.com/id/01a0f094-b837-76de-94de-1fdabf2c1fc1.jsonld), [N-Triples](https://ontology.bommaritollc.com/id/01a0f094-b837-76de-94de-1fdabf2c1fc1.nt), [HTML](https://ontology.bommaritollc.com/id/01a0f094-b837-76de-94de-1fdabf2c1fc1)
Cite as: 21 CFR Part 201—Labeling. bc-ontology, release 0.1.0-rc38, 2026-10-21. https://ontology.bommaritollc.com/id/01a0f094-b837-76de-94de-1fdabf2c1fc1
Release 0.1.0-rc38, graph hash 05350a11cf9d0c42fba51e92b877115781ab65cb92afcd6b172ff9f8f4abf0bd.
